GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4d pharma PLC (LSE:DDDD) » Definitions » Insider Ownership

4d pharma (LSE:DDDD) Insider Ownership : 15.68 % (As of May. 31, 2024)


View and export this data going back to 2014. Start your Free Trial

What is 4d pharma Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, 4d pharma's insider ownership is 15.68%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, 4d pharma's Institutional Ownership is 8.82%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, 4d pharma's Float Percentage Of Total Shares Outstanding is 0.00%.


4d pharma Insider Ownership Historical Data

The historical data trend for 4d pharma's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4d pharma Insider Ownership Chart

4d pharma Historical Data

The historical data trend for 4d pharma can be seen below:

2022-04-30 2022-05-31 2022-06-30 2022-07-31 2022-08-31 2022-09-30 2022-10-31 2022-11-30 2022-12-31 2023-01-31
Insider Ownership 15.68 15.68 15.68 15.68 15.68 15.68 15.68 15.68 15.68 15.68

4d pharma Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


4d pharma (LSE:DDDD) Business Description

Traded in Other Exchanges
N/A
Address
9 Bond Court, Fifth Floor, Leeds, GBR, LS1 2JZ
4d pharma PLC and its subsidiaries are in the business of research and development and production of live biotherapeutic products. The company develops biotherapeutic products for diseases such as cancer, asthma, autism, and autoimmune conditions such as arthritis and multiple sclerosis. Its developing science includes Live biotherapeutics, Microbiome, MicroRx, MicroDx, and others.

4d pharma (LSE:DDDD) Headlines

No Headlines